Construction of prediction model for KRAS mutation status of colorectal cancer based on CT radiomics

被引:9
|
作者
Cao, Yuntai [1 ,2 ,3 ,4 ]
Zhang, Jing [5 ]
Huang, Lele [6 ]
Zhao, Zhiyong [7 ]
Zhang, Guojin [8 ,9 ]
Ren, Jialiang [10 ]
Li, Hailong [11 ]
Zhang, Hongqian [11 ]
Guo, Bin [11 ]
Wang, Zhan [11 ]
Xing, Yue
Zhou, Junlin [2 ,3 ,4 ]
机构
[1] Qinghai Univ, Affiliated Hosp, Dept Radiol, Tongren Rd 29, Xining 810001, Peoples R China
[2] Lanzhou Univ, Hosp 2, Dept Radiol, Cuiyingmen 82, Lanzhou 730030, Peoples R China
[3] Key Lab Med Imaging Gansu Prov, Lanzhou 730030, Peoples R China
[4] Gansu Int Sci & Technol Cooperat Base Med Imaging, Lanzhou 730030, Peoples R China
[5] Zunyi Med Univ, Affiliated Hosp 5, Zunyi 519100, Peoples R China
[6] Lanzhou Univ, Hosp 2, Dept Nucl Med, Lanzhou, Peoples R China
[7] Lanzhou Univ, Hosp 2, Dept Neurosurg, Lanzhou, Peoples R China
[8] Sichuan Acad Med Sci, Chengdu, Peoples R China
[9] Sichuan Prov Peoples Hosp, Chengdu, Peoples R China
[10] GE Healthcare, Dept Pharmaceut Diag, Beijing, Peoples R China
[11] Qinghai Univ, Affiliated Hosp, Xining, Peoples R China
基金
中国国家自然科学基金;
关键词
KRAS mutation; Colorectal cancer; Radiomics; CT; Triphasic enhanced phase; K-RAS MUTATIONS; TEXTURE ANALYSIS; HETEROGENEITY; PET/CT; CARCINOMA; DIAGNOSIS; CETUXIMAB;
D O I
10.1007/s11604-023-01458-3
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
BackgroundIn this study, we used computed tomography (CT)-based radiomics signatures to predict the mutation status of KRAS in patients with colorectal cancer (CRC) and to identify the phase of radiomics signature with the most robust and high performance from triphasic enhanced CT.MethodsThis study involved 447 patients who underwent KRAS mutation testing and preoperative triphasic enhanced CT. They were categorized into training (n = 313) and validation cohorts (n = 134) in a 7:3 ratio. Radiomics features were extracted using triphasic enhanced CT imaging. The Boruta algorithm was used to retain the features closely associated with KRAS mutations. The Random Forest (RF) algorithm was used to develop radiomics, clinical, and combined clinical-radiomics models for KRAS mutations. The receiver operating characteristic curve, calibration curve, and decision curve were used to evaluate the predictive performance and clinical usefulness of each model.ResultsAge, CEA level, and clinical T stage were independent predictors of KRAS mutation status. After rigorous feature screening, four arterial phase (AP), three venous phase (VP), and seven delayed phase (DP) radiomics features were retained as the final signatures for predicting KRAS mutations. The DP models showed superior predictive performance compared to AP or VP models. The clinical-radiomics fusion model showed excellent performance, with an AUC, sensitivity, and specificity of 0.772, 0.792, and 0.646 in the training cohort, and 0.755, 0.724, and 0.684 in the validation cohort, respectively. The decision curve showed that the clinical-radiomics fusion model had more clinical practicality than the single clinical or radiomics model in predicting KRAS mutation status.ConclusionThe clinical-radiomics fusion model, which combines the clinical and DP radiomics model, has the best predictive performance for predicting the mutation status of KRAS in CRC, and the constructed model has been effectively verified by an internal validation cohort.
引用
收藏
页码:1236 / 1246
页数:11
相关论文
共 50 条
  • [21] KRAS-mutation status in Brazilian patients with colorectal cancer
    Segatelli, V.
    Christie de Oliveira, E.
    Ramos da Costa, A.
    Sobroza de Mello, E.
    Avancini Ferreira Alves, V.
    VIRCHOWS ARCHIV, 2014, 465 : S227 - S227
  • [22] Schistosoma infection, KRAS mutation status, and prognosis of colorectal cancer
    Li, Xinyi
    Liu, Hongli
    Huang, Bo
    Yang, Ming
    Fan, Jun
    Zhang, Jiwei
    Weng, Mixia
    Yan, Zhecheng
    Liu, Li
    Cai, Kailin
    Nie, Xiu
    Chang, Xiaona
    CHINESE MEDICAL JOURNAL, 2024, 137 (02) : 235 - 237
  • [23] Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
    Yang, Lei
    Dong, Di
    Fang, Mengjie
    Zhu, Yongbei
    Zang, Yali
    Liu, Zhenyu
    Zhang, Hongmei
    Ying, Jianming
    Zhao, Xinming
    Tian, Jie
    EUROPEAN RADIOLOGY, 2018, 28 (05) : 2058 - 2067
  • [24] Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
    Lei Yang
    Di Dong
    Mengjie Fang
    Yongbei Zhu
    Yali Zang
    Zhenyu Liu
    Hongmei Zhang
    Jianming Ying
    Xinming Zhao
    Jie Tian
    European Radiology, 2018, 28 : 2058 - 2067
  • [25] CT-based radiomics: A potential indicator of KRAS mutation in pulmonary adenocarcinoma
    Mahmoud, Menna Allah
    Wu, Sijun
    Su, Ruihua
    Liufu, Yuling
    Wen, Yanhua
    Pan, Xiaohuan
    Guan, Yubao
    TUMORI JOURNAL, 2025, 111 (02): : 147 - 157
  • [26] Predicting Kirsten Rat Sarcoma Virus Gene Mutation Status in Patients With Colorectal Cancer by Radiomics Models Based on Multiphasic CT
    Hu, Jianfeng
    Xia, Xiaoying
    Wang, Peng
    Peng, Yu
    Liu, Jieqiong
    Xie, Xiaobin
    Liao, Yuting
    Wan, Qi
    Li, Xinchun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
    Radanova, Maria
    Mihaylova, Galya
    St Stoyanov, George
    Draganova, Vyara
    Zlatarov, Aleksandar
    Kolev, Nikola
    Dimitrova, Eleonora
    Conev, Nikolay
    Ivanova, Diana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [28] GENETIC ANALYSIS OF KRAS MUTATION STATUS IN METASTATIC COLORECTAL CANCER PATIENTS
    Zavodna, K.
    Konecny, M.
    Spanik, S.
    Galbavy, S.
    Vizvaryova, M.
    Weismanova, E.
    Kausitz, J.
    ANTICANCER RESEARCH, 2008, 28 (6B) : 4015 - 4016
  • [29] KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
    Lievre, A.
    Bachet, J.
    Boige, V
    Landi, B.
    Emile, J.
    Cote, J.
    Tomasic, G.
    Rougier, P.
    Penault-Llorca, F.
    Laurent-Puig, P.
    ANNALS OF ONCOLOGY, 2006, 17 : 42 - 42
  • [30] Genetic analysis of KRAS mutation status in metastatic colorectal cancer patients
    Zavodna, K.
    Konecny, M.
    Krivulcik, T.
    Spanik, S.
    Behulova, R.
    Vizvaryova, M.
    Weismanova, E.
    Galbavy, S.
    Kausitz, J.
    NEOPLASMA, 2009, 56 (03) : 275 - 278